Phase 2 N=30 Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Lymphoma
Primary: Overall Response Rate — 15; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=58 Hoarding Older Adults
Compulsive Hoarding
Primary: Hoarding Symptom Severity as Measured by the Saving Inventory-Revised (SI-R) at 6 Months — 35.44; 44.68 units on a scale — p=.029
Phase 3 N=602 Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Hepatitis C
Primary: Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 85.1; 81.3 Percentage of participants
Phase 2 N=24 Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin
Metabolic Syndrome
Primary: Waist Circumference (WC) — 101; 96 cm — p=0.57
N/A N=120 Vaginal Cuff Dehiscence and Thermal Injury During TLH
Vaginal Cuff Dehiscence · Thermal Injury
Primary: Degree of Thermal Injury at the Time of Laparoscopic Hysterectomy — 0.68; 0.63; 0.66; 0.70 mm
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
N/A N=36 Comparative Effects of Aspirin and NHP-544C
Healthy
Primary: Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose — 0.181; 0.255 ng/mg creatinine
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
N/A N=443 An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
Skin Cancer
Primary: Indoor Tanning Behavior — 5.29; 6.30 Indoor tanning sessions over past year — p=.633
N/A N=108 An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Anemia
Primary: Mean Height of Participants at Baseline (Week 0) — 163.15 cm
N/A N=27,251 IMPACCT for Kids' Care
Insurance Status/Stability
Primary: Percent of Study Period Covered by Medicaid — 30; 451; 297; 113 participants
Phase 4 N=62 A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
Attention Deficit Hyperactivity Disorder
Primary: Medication Event Monitoring System (MEMS®) Dosage Adherence — 42.7; 66.2 percentage of participants adherent
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
Phase 2 N=60 Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery
Cataract
Primary: Mean Aqueous Humor Bromfenac Concentration — 49.3; 23.7 ng/mL